Drreddys Laboratories | RDY - Sales Revenues


Drreddys Laboratories reported INR789.05M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Bayer EUR 13.41B 1.97B Mar/2026
Canopy Growth CAD 74.54M 7.86M Dec/2025
Cipla INR 65.41B 9.77B Mar/2026
Corcept Therapeutics USD 164.9M 37.22M Mar/2026
Drreddys Laboratories INR 789.05M 86.48B Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Novartis USD 13.11B 226M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 281.62M 1.82M Mar/2026
Richter Gedeon HUF 214.69B 26.79B Sep/2025
Sun Pharmaceuticals INR 147.99B 3.21B Dec/2025
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026